Dopavision is a Berlin-based company developing digital therapeutics for myopia. Nearsightedness (myopia) is a vision condition in which patients can see objects near to them clearly, but objects farther away are blurry.
Dopavision raises Series A round
In a recent development, the company announced that it has raised €12M in its Series A round of funding. The round was led by Seventure Partners and was joined by Novartis Pharmaceuticals.